MARKET

AUTL

AUTL

AUTOLUS THERAPEUTICS PLC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.380
+0.080
+2.42%
Closed 19:41 08/10 EDT
OPEN
3.450
PREV CLOSE
3.300
HIGH
3.450
LOW
3.100
VOLUME
70.03K
TURNOVER
--
52 WEEK HIGH
7.90
52 WEEK LOW
1.960
MARKET CAP
307.28M
P/E (TTM)
-1.8325
1D
5D
1M
3M
1Y
5Y
Autolus Therapeutics Earlier Reported Q2 EPS $(0.46) Beats $(0.51) Estimate
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 2.13 percent increase over losses of $(0.47) per share from
Benzinga · 6d ago
Recap: Autolus Therapeutics Q2 Earnings
  Autolus Therapeutics (NASDAQ:AUTL) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 6d ago
Autolus Therapeutics GAAP EPS of -$0.46 misses by $0.13
Autolus Therapeutics press release (<span clas...
Seekingalpha · 08/04 11:12
Autolus Therapeutics Reports Second Quarter 2022 Financial Results and Operational Progress
- Conference call to be held on August 4, 2022 at 8:30 am ET/1:30 pm BST -LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, ...
GlobeNewswire · 08/04 11:00
Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call, and replaces the earlier version LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc ...
GlobeNewswire · 07/21 11:54
Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2022 financial res...
GlobeNewswire · 07/21 11:00
Is Autolus Therapeutics (NASDAQ:AUTL) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 07/11 10:00
Autolus Therapeutics to Participate in William Blair’s Biotech Focus Conference 2022, New York, July 12 – 13, 2022
LONDON, July 06, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that management will be attending William Blair’s Biotech ...
GlobeNewswire · 07/06 11:00
More
No Data
Learn about the latest financial forecast of AUTL. Analyze the recent business situations of AUTOLUS THERAPEUTICS PLC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

27.27%Strong Buy
45.45%Buy
27.27%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AUTL stock price target is 12.06 with a high estimate of 20.00 and a low estimate of 3.500.
High20.00
Average12.06
Low3.500
Current 3.380
EPS
Actual
Estimate
-0.41-0.31-0.20-0.10
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 90
Institutional Holdings: 75.50M
% Owned: 83.05%
Shares Outstanding: 90.91M
TypeInstitutionsShares
Increased
16
2.62M
New
9
5.39M
Decreased
26
2.88M
Sold Out
15
4.39M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About AUTL
Autolus Therapeutics PLC is a biopharmaceutical company. The Company is focused on developing programmed T cell therapies for the treatment of cancer. It has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO1/22, AUTO4, AUTO6NG and AUTO8. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO1/22 is a dual-targeting CAR-T which builds on the Obe-cel approach utilizing CD19 CAR. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. AUTO8 is used to treat myeloma.

Webull offers kinds of Autolus Therapeutics PLC stock information, including NASDAQ:AUTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUTL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AUTL stock methods without spending real money on the virtual paper trading platform.